Recent insights into the biology of Barrett's esophagus-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Recent insights into the biology of Barrett's esophagus

Published:2020-07-17 Issue:1 Volume:1481 Page:198-209
ISSN:0077-8923
Container-title:Annals of the New York Academy of Sciences
language:en
Short-container-title:Ann. N.Y. Acad. Sci.

Author:

Badgery Henry¹,Chong Lynn¹,Iich Elhadi²,Huang Qin³,Georgy Smitha Rose⁴,Wang David H.⁵,Read Matthew¹⁶

Affiliation:

1. Department of Upper Gastrointestinal Surgery St Vincent's Hospital Melbourne Victoria Australia

2. Cancer Biology and Surgical Oncology Laboratory Peter MacCallum Cancer Centre Melbourne Victoria Australia

3. Department of Pathology and Laboratory Medicine Veterans Affairs Boston Healthcare System and Harvard Medical School West Roxbury Massachusetts

4. Department of Anatomic Pathology, Faculty of Veterinary and Agricultural Sciences The University of Melbourne Melbourne Victoria Australia

5. Department of Hematology and Oncology UT Southwestern Medical Centre and VA North Texas Health Care System Dallas Texas

6. Department of Surgery The University of Melbourne, St Vincent's Hospital Melbourne Victoria Australia

Publisher

Wiley

Subject

History and Philosophy of Science,General Biochemistry, Genetics and Molecular Biology,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/nyas.14432

Reference96 articles.

1. Biology of Barrett's Esophagus and Esophageal Adenocarcinoma

2. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

3. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

4. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial

5. Predicting the Future Burden of Esophageal Cancer by Histological Subtype: International Trends in Incidence up to 2030

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Esophageal Mucosal Resistance in Reflux Esophagitis: What We Have Learned So Far and What Remains to Be Learned;Diagnostics;2023-08-12

2. The Oxidative Damage and Inflammation Mechanisms in GERD-Induced Barrett’s Esophagus;Frontiers in Cell and Developmental Biology;2022-05-26

3. Tumor cell malignancy: A complex trait built through reciprocal interactions between tumors and tissue-body system;iScience;2022-05

4. Do proton pump inhibitors prevent Barrett’s esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis;Journal of Cancer Research and Clinical Oncology;2021-02-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3